JUL 29, 2020 8:00 AM EDT

High-throughput DNA damage analyses identify synergistic drug combinations to treat malignant brain tumours

C.E. Credits: P.A.C.E. CE Florida CE
Speaker
  • Asst. Professor, Dept. of Pharmacology and Therapeutics, University of Manitoba; Senior Scientist, Research Institute in Oncology and Hematology, CancerCare Manitoba, Canada
    Biography

      Sachin Katyal received his B.Sc. (Biochemistry) from the University of Alberta and received his Ph.D. (Oncology) at the Cross Cancer Institute and the University of Alberta. His post-doctoral training, at St. Jude Children’s Research Hospital, in the area of DNA damage and repair in neurodevelopment and neuro-oncology was done in the lab of Dr. Peter McKinnon; work that led to publications in internationally-renowned journals such as Nature, Nature Neuroscience and EMBO J. In 2013, Dr. Katyal began his independent academic research position at the University of Manitoba and CancerCare Manitoba where he is an Assistant Professor within the Department of Pharmacology and Therapeutics (D-PT) and, a Senior Scientist within the Research Institute of Oncology and Hematology (RIOH). Dr. Katyal’s research is CIHR- and TFRI-funded; he is the recipient of the CIHR Institute of Cancer Research 2014 Early Career Award in Cancer Research, a CIHR New Investigator award and a TFRI New Investigator Award. He serves on several scientific review committees for international academic journals and grant review panels. More recently, Sachin established industrial partnerships, which have facilitated the development of innovative technology and methodology to accelerate his DNA damage repair research program; instrumental for development of his novel high-throughput genotoxicity and drug screening facility to understand and identify new therapies against brain tumours and leukemia. Sachin is also actively involved in trainee development, mentorship and career progression through various University-, National- and International-wide initiatives, courses and workshops.


    Abstract

    Current methods to treat malignant brain tumors are highly intrusive, leading to poor quality of life with abysmal patient survival rates. Combined with radiation therapy, first/second-line DNA damaging chemotherapeutics marginally improve patient survival. However, high rates of drug-resistance and recurrence are due to development of intra/intertumoral heterogeneity due in part from the emergence of chemoradioresistant clones. The targeted use of DNA repair inhibitors to sensitize and augment tumour cell killing is an emerging tool in cancer therapy. However, the biochemical and functional readout of combining chemotherapeutic drugs with one or more DNA damaging inhibitors is limited by use of traditionally low-throughput analytical techniques that preclude their adequate interrogation and translational potential.

    We have developed novel high-throughput DNA repair assay methods, which allow us to combine multiple DNA repair inhibitors and genotoxic agents in order to identify synergistic interactions that sensitize CNS tumours to chemoradiotherapeutics. This combinatorial analysis approach combines DNA damage, cell cycle and cell viability readouts for determining drug selection and dosing effectiveness.

    Part 1 of my talk will detail our development of a high-throughput comet assay (HTCOMET) that enables simultaneous, unbiased multi-well/sample DNA damage analysis. Using this strategy, we have compared drug/repair inhibitor responses amongst patentderived glioblastoma multiforme (GBM) and medulloblastoma (MB) cell lines. Using this approach we have found differential sensitivities amongst tumor types and amongst tumor lines. Validation studies have identified key molecular differences that prescribe these differential sensitivities.

    Part 2 of my talk will outline our development of the high-throughput γH2AX analysis (HT-γH2AX) whereby γH2AX imaging and foci quantification has enabled a detailed examination of poly(ADP-ribose) polymerase inhibitor (PARPi) use in GBM lines in conjunction with the first-line DNA alkylating agent, Temozolomide (TMZ), and secondline DNA Toposiomase-1 inhibitor, Topotecan (TPT). This analysis has enabled a new level of molecular insight into the properties of these drugs whereby γH2AX foci analysis combined with predictive markers of the DDR pathway and cell cycle analysis (in both dose-escalating and time-dependent manners) identify specific properties in select PARPis that can synergize with chemotherapeutics to better enable tumor cell killing.

    Our novel high-throughput DNA damage assay methodology enables molecular dissection and understanding of the interplay of DNA repair pathways with broad implications to fundamental science and clinical treatment. Fast, efficient and reproducible analyses, drug-screening and validation can be achieved using patientderived tumor specimens and live cells to identify targeted and/or personalized therapies for improved patient outcomes.

     

    Learning Objectives:

    1. To understand the cellular DNA damage response and types of DNA repair pathways

    2. To identify DNA damage-specific repair pathways that brain tumor cells use to resolve damage induced by chemotherapy which act to evade cell death.

    3. To describe how conventional low-throughput DNA repair methodologies can be streamlined using unbiased semi-automated high-throughput techniques to enable drug combination synergy analysis and drug discovery through the lens of DNA damage repair – a fundamental outcome of most anti-cancer chemotherapeutics.


    Show Resources
    You May Also Like
    SEP 10, 2020 9:00 AM PDT
    C.E. CREDITS
    SEP 10, 2020 9:00 AM PDT
    Date: September 10, 2020 Time: 9:00am (PDT), 12:00pm (EDT) Osmolality testing is relevant throughout the entire bioprocessing workflow. As customers look to refine mAb and gene therapy workf...
    FEB 24, 2021 10:00 AM PST
    C.E. CREDITS
    FEB 24, 2021 10:00 AM PST
    DATE: February 24, 2021 TIME: 10am PST Automated lab instruments such as liquid handlers and cell sorters are increasingly common in all types of laboratories, driving fast results for labor...
    SEP 03, 2020 9:00 AM PDT
    C.E. CREDITS
    SEP 03, 2020 9:00 AM PDT
    DATE: September 3, 2020 TIME: 09:00am PT, 12:00pm ET xxx Learning Objectives: xxx Webinars will be available for unlimited on-demand viewing after live event. LabRoots is approved as a provi...
    DEC 03, 2020 4:30 PM PST
    C.E. CREDITS
    DEC 03, 2020 4:30 PM PST
    This drug development program is designed to create a family of broad-spectrum, pan-coronaviral drugs that respectively inhibit multiple key enzymes required for viral replication. By target...
    JAN 21, 2021 8:00 AM PST
    JAN 21, 2021 8:00 AM PST
    Date: January 21, 2021 Time: 8:00am (PST), 11:00am (EST) Today, critical reagent characterization is a key component in the overall workflow to establish robust ligand binding assays (e.g.,...
    NOV 05, 2020 7:00 AM PST
    C.E. CREDITS
    NOV 05, 2020 7:00 AM PST
    DATE: Date needed, 2020 TIME: Time needed Exosomes are a population of naturally occurring mobile, membrane-limited, 30 – 100 nm in diameter, extracellular vesicles containing a large...
    Loading Comments...
    Show Resources